跳至主要内容
临床试验/NCT00638053
NCT00638053终止4 期

Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury

Pfizer5 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2002年11月最近更新:
适应症

试验速览

阶段
4 期
状态
终止
发起方
Pfizer
入组人数
100
试验地点
5
主要终点
Change in the serum Insulin-like growth factor-I (IGF-I)concentration from baseline

研究概览

简要总结

The purpose of this study is to assess the prevalence of GHD in patients who sustain a head injury or suffer a major traumatic event and to evaluate the efficacy of growth hormone (GH) therapy in the treatment of GHD caused by trauma or head injury

详细描述

The study was terminated on October 9, 2003. The reason cited for the termination was due to poor patient recruitment and therefore not enough data could be collected to provide comprehensive analysis for reporting of results. No safety or efficacy issues were reported to cause the termination of the study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Documented GHD
  • Documented mild, moderate, and severe head injury (e.g.,Glasgow COMA Scale score less than or equal to 15 or equivalent measure)

排除标准

  • Active systemic malignancy or active intracranial tumor
  • Growth hormone replacement therapy in the last 12 months
  • History of dementia unrelated to traumatic brain injury

结局指标

主要结局

Change in the serum Insulin-like growth factor-I (IGF-I)concentration from baseline

时间窗: Months 1 thru 11

Number of patients with abnormal GH stimulation tests

时间窗: Baseline

次要结局

  • Change from baseline in waist circumference(Month 12)
  • Age and gender specific optimal doses of GH replacement(Months 1 thru 11)
  • Change in Quality of Life-Adult Growth Hormone Deficiency Assessment(Months 1 thru 12)
  • Assessment of adverse events(Months 1 thru 12)
  • Serum prolactin, thyroid stimulating hormone, free thyroxine serum, cortisol, adrenocorticotropic hormone, luteinizing hormone, follicle stimulating hormone, estradiol, and testosterone to assess degree of other anterior pituitary hormone deficiencies(Baseline)
  • Change from baseline in Glasgow Outcome Score(Month 12)
  • Change in Quality of Life-Mini-Mental scores(Months 1 thru 12)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验